KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.

Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez-Ruixo

CPT Pharmacometrics Syst Pharmacol 14(10) 1562-1574

PMID40613748
PMCIDPMC12521056
DOI10.1002/psp4.70061
发表日期2025-07-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure-response (E-R) relationships of selected efficacy and safety endpoints. Ibrutinib PK was consistent with previous assessments, characterized by an open two-compartment disposition model with sequential zero-first order oral absorption after a lag time. Ibrutinib treatment was efficacious in extending PFS versus placebo (HR: 0.75; 95% CI: 0.59 to 0.96), although similar OS, CRR, and ORR were observed. PFS benefit was similar across the quartiles of ibrutinib exposure, suggesting that systemic exposures obtained provide maximal clinical response. There was no association between ibrutinib exposure and incidence of major hemorrhage, Grade ≥ 3 liver function test abnormalities, Grade ≥ 3 neutropenia, Grade ≥ 2 diarrhea, treatment-emergent adverse events (TEAEs) leading to death, and TEAEs leading to ibrutinib dose reduction. However, the incidence of all Grade ≥ 3 TEAEs, all serious TEAEs, TEAEs leading to ibrutinib discontinuation, Grade ≥ 1 atrial fibrillation, any hemorrhage, and Grade ≥ 3 infection was higher in the ibrutinib than placebo arm. Of these, only atrial fibrillation and any hemorrhage increased with increasing exposure. Overall, ibrutinib 560 mg, combined with BR, consistently improves PFS across the ibrutinib exposure range evaluated. According to the results of the exposure-response analysis, for patients who develop specific toxicities, dose reduction according to the prescribing information may improve the ibrutinib tolerability while keeping adequate exposure to maintain efficacy.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 1

FIGURE 1 Kaplan–Meier plots of PFS (A) and OS (B) stratified by quartiles of ibrutinib AUC τ,ss and efficacy response rates by quartiles of ibrutinib AUC τ,ss (C). Dots show different efficacy endpoint incidences (and 95% CI) at the median ibrutinib AUC t,ss for each ibrutinib AUC t,ss quartile. Dashed lines show the boundaries of the quartiles. Horizontal lines show incidence in placebo arm (black), and the associated 95% CI (gray). [Correction added on 10 July 2025, after first online publication: Resolution for Figure 1 has been updated in this version.]

A

PFS

FIGURE 1 · Panel A

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:flat topline artifact
查看结果
B

OS

FIGURE 1 · Panel B

failed 待 EXE 对齐 预期 5 条 已提取 0 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 2FIGURE 2 Incidence of TEAEs by Quartiles of Ibrutinib AUC τ,ss . Afib = atrial fibrillation; AUC t,ss = area under the concentration curve during 24 h after dosing at steady state; CI = confidence interval; SAE = serious adverse event (treatment‐emergent); TEAE = treatment‐emergent adverse event. Dots show different safety endpoint incidences (and 95% CI) at the median ibrutinib AUC t,ss for each ibrutinib AUC t,ss quartile. Dashed lines show the boundaries of the quartiles. Horizontal lines show incidence in placebo arm (black), and the associated 95% CI (gray).
非 KM Figure
FIGURE 3FIGURE 3 Predicted Effect of Ibrutinib AUC τ,ss on the Incidence of Afib (A) and Any Hemorrhage (B) and Any Hemorrhage by CYP3A Inhibitor (C). (A, B) Afib = atrial fibrillation; AUCss = AUC t,ss = area under the concentration curve during 24 h after dosing at steady state; CI = confidence interval; vs. = versus. Black line: model prediction Afib or any hemorrhage versus ibrutinib AUC t,ss . Gray area: 95% CI of the model prediction. Colored vertical ticks indicate the ibrutinib AUC t,ss for each individual; blue lines are for “event,” red lines are for “no event.” Dots: observed frequency of event, by exposure quartile, with 95% CI. (C) Any = mild, moderate, or strong CYP3A inhibitor comedication; AUC ss = AUC t,ss = area under the concentration curve during 24 h after dosing at steady state; CI = confidence interval; none = no CYP3A inhibitor comedication; vs. = versus. Black line: Model prediction of any hemorrhage versus ibrutinib AUC t,ss . Gray area: 95% CI of the model prediction. Colored vertical ticks indicate the ibrutinib AUC t,ss for each individual; blue for event, red for no event. Dots: observed frequency of event, by exposure quartile, with 95% CI.
非 KM Figure